恩度肝动脉灌注联合化疗栓塞治疗晚期肝癌的近期疗效观察

Short-term efficacy of hepatic arterial infusion with endostar combined with chemoembolization for Advanced liver cancer

目的观察恩度肝动脉灌注联合化疗栓塞治疗晚期肝癌的临床效果。方法选取78例晚期肝癌患者,其中采用化疗栓塞治疗的39例为对照组,采用恩度肝动脉灌注联合化疗栓塞治疗的39例为观察组。比较两组治疗总有效率、生存率、甲胎蛋白、细胞免疫功能及生存质量。结果观察组临床疗效优于对照组,差异有统计学意义(P<0.05)。观察组CD3、CD4、NK细胞水平及CD4/CD8比例均高于对照组,甲胎蛋白水平低于对照组,差异均有统计学意义(P<0.05)。观察组生存率高于对照组,差异有统计学意义(P<0.05)。观察组五种功能、三种症状及整体健康状况得分均高于对照组,差异有统计学意义(P<0.05)。结论晚期肝癌患者应用恩度肝动脉灌注联合化疗栓塞治疗可获得良好疗效,既可改善甲胎蛋白、细胞免疫功能,又可提高患者的生存率及生存质量,值得临床推广应用。

Objective To investigate the clinical efficacy of hepatic arterial infusion with endostar combined with chemoembolization for late-stage liver cancer. Methods Seventy-eight patients with Advanced liver cancer were enrolled, including 39 cases treated with chemoembolization（control group） and 39 cases treated with hepatic arterial infusion with endostar combined with chemoembolization （observation group）. The total therapeutic effective rate, survival rate, alpha-fetoprotein （AFP）, cellular immune function and quality of life were compared between the two groups. Results The clinical efficacy of the observation group was superior to that of the control group（ P 〈0.05）. Compared to the control group, the levels of CD3, CD4 and NK cells and the ratio of CD4/CD8 were higher, but AFP level was lower in the observation group（ P 〈0.05 ）. The survival rate of the observation group was higher than that of the control group（ P 〈0.05）. The scores of 5 types of function, 3 symptoms and total health condition were higher in the observation group compared to the control group（ P 〈0.05）. Conclusion Application of hepatic arterial infusion with endostar combined with chemoembolization can obtain a good efficacy for advanced liver cancer, not only can improve the AFP level and cellular immune function, but also improve the survival rate and quality of life. It is worthy of clinical promotion and application.